- Home
- Publications
- Publication Search
- Publication Details
Title
Broad-Spectrum Antiviral Strategies and Nucleoside Analogues
Authors
Keywords
-
Journal
Viruses-Basel
Volume 13, Issue 4, Pages 667
Publisher
MDPI AG
Online
2021-04-13
DOI
10.3390/v13040667
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Shifts in global bat diversity suggest a possible role of climate change in the emergence of SARS-CoV-1 and SARS-CoV-2
- (2021) Robert M. Beyer et al. SCIENCE OF THE TOTAL ENVIRONMENT
- Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
- (2021) Goran Kokic et al. Nature Communications
- Medicinal chemistry strategies toward host targeting antiviral agents
- (2020) Xingyue Ji et al. MEDICINAL RESEARCH REVIEWS
- Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
- (2020) Emmie de Wit et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural basis for RNA replication by the SARS-CoV-2 polymerase
- (2020) Quan Wang et al. CELL
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Compassionate Use of Remdesivir for Patients with Severe Covid-19
- (2020) Jonathan Grein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir: Review of pharmacology, pre‐clinical data and emerging clinical experience for COVID‐19
- (2020) Sarah CJ Jorgensen et al. PHARMACOTHERAPY
- Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
- (2020) Wanchao Yin et al. SCIENCE
- The novel zoonotic COVID-19 pandemic: An expected global health concern
- (2020) Carlo Contini et al. Journal of Infection in Developing Countries
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
- (2020) Qingxian Cai et al. Engineering
- Reprogramming of the Antibacterial Drug Vancomycin Results in Potent Antiviral Agents Devoid of Antibacterial Activity
- (2020) Zsolt Szűcs et al. Pharmaceuticals
- Remdesivir against COVID-19 and Other Viral Diseases
- (2020) Jakob J. Malin et al. CLINICAL MICROBIOLOGY REVIEWS
- Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis
- (2020) Ashleigh Shannon et al. Nature Communications
- Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
- (2019) Egor Tchesnokov et al. Viruses-Basel
- The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold
- (2018) Katherine L. Seley-Radtke et al. ANTIVIRAL RESEARCH
- Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
- (2018) Leen Delang et al. ANTIVIRAL RESEARCH
- Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies
- (2018) Vinicius Lins Ferreira et al. CLINICAL DRUG INVESTIGATION
- Uso de ribavirina en virus distintos de la hepatitis C . Una revisión de la evidencia
- (2018) German Ramírez-Olivencia et al. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
- History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: a review
- (2018) Tiago Souza Salles et al. Parasites & Vectors
- Drug Repurposing for Viral Infectious Diseases: How Far Are We?
- (2018) Beatrice Mercorelli et al. TRENDS IN MICROBIOLOGY
- Nucleobases and corresponding nucleosides display potent antiviral activities against dengue virus possibly through viral lethal mutagenesis
- (2018) Li Qiu et al. PLoS Neglected Tropical Diseases
- Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus
- (2018) Juan-Carlos Saiz et al. Viruses-Basel
- The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold
- (2018) Mary K. Yates et al. ANTIVIRAL RESEARCH
- Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
- (2017) Dustin Siegel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
- (2017) Thi Huyen Tram Nguyen et al. PLoS Neglected Tropical Diseases
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
- (2016) Travis K. Warren et al. NATURE
- Zika Virus and Birth Defects — Reviewing the Evidence for Causality
- (2016) Sonja A. Rasmussen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
- (2016) Daouda Sissoko et al. PLOS MEDICINE
- Dose regimen of favipiravir for Ebola virus disease
- (2015) France Mentré et al. LANCET INFECTIOUS DISEASES
- Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers
- (2015) Michael Jacobs et al. LANCET INFECTIOUS DISEASES
- First report of autochthonous transmission of Zika virus in Brazil
- (2015) Camila Zanluca et al. MEMORIAS DO INSTITUTO OSWALDO CRUZ
- MERS coronavirus: diagnostics, epidemiology and transmission
- (2015) Ian M. Mackay et al. Virology Journal
- Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase
- (2013) Hidehiro Sangawa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Favipiravir (T-705), a novel viral RNA polymerase inhibitor
- (2013) Yousuke Furuta et al. ANTIVIRAL RESEARCH
- Structure–Activity Relationships and Design of Viral Mutagens and Application to Lethal Mutagenesis
- (2013) Laurent F. Bonnac et al. JOURNAL OF MEDICINAL CHEMISTRY
- T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro
- (2013) T. Baranovich et al. JOURNAL OF VIROLOGY
- Risk in Vaccine Research and Development Quantified
- (2013) Esther S. Pronker et al. PLoS One
- The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase
- (2013) Zhinan Jin et al. PLoS One
- RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex
- (2012) M. Bouvet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterizing the Epidemiology of the 2009 Influenza A/H1N1 Pandemic in Mexico
- (2011) Gerardo Chowell et al. PLOS MEDICINE
- Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection
- (2010) Nassim Kamar et al. GASTROENTEROLOGY
- Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
- (2010) Michael J. Sofia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Viral Mutation Rates
- (2010) R. Sanjuan et al. JOURNAL OF VIROLOGY
- Evaluation of the role of three candidate human kinases in the conversion of the hepatitis C virus inhibitor 2′-C-methyl-cytidine to its 5′-monophosphate metabolite
- (2009) Nina L. Golitsina et al. ANTIVIRAL RESEARCH
- The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4′-azidocytidine (R1479)
- (2009) Christopher McGuigan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The phosphoramidate ProTide approach greatly enhances the activity of β-2′-C-methylguanosine against hepatitis C virus
- (2009) Christopher McGuigan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo
- (2009) J. M. Cuevas et al. JOURNAL OF VIROLOGY
- Physicochemical Properties of the Nucleoside Prodrug R1626 Leading to High Oral Bioavailability
- (2008) Michael Brandl et al. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation